ZED1227 clinical trials
How each study uses ZED1227 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ZED1227 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ZED1227.
- Aug 2027Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac DiseasePhase 2 · Dr. Falk Pharma GmbH
Studies
Open first, then newest update. How each study uses ZED1227 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac DiseaseRecruitingPhase 2Dr. Falk Pharma GmbHNCT07298343Written as ZED1227 + SIGE
- A Study of TAK-227 in Healthy AdultsCompletedPhase 1TakedaNCT05818956Written as TAK-227
- Different Doses of ZED1227 vs. Placebo in NAFLDCompletedPhase 2Dr. Falk Pharma GmbHNCT05305599Written as ZED1227